Company Analysis

Neuphoria Therapeutics Inc. (NEUP)

Nasdaq: NEUP · Pharmaceutical Preparations · Burlington, MA · filing with the SEC since 2002
Grade4.5
◀ Past 3.5● Present 4.4▶ Future 5.1
5 est.

Filings

199 filings since 2017 beside 20 insider forms · Non-accelerated filer and smaller reporting company and emerging growth company · read from EDGAR on Nov 13, 2026
Due nextNon-accelerated filer and smaller reporting company and emerging growth company
10-Q Quarterly report for the quarter ending Sep 30, 2026Non-accelerated filers and smaller reporting companies have 45 days after the quarter ends; quarter ends are taken to the month end. by Nov 14, 2026
10-K Annual report for the fiscal year ending Jun 30, 2027Non-accelerated filers and smaller reporting companies have 90 days after the fiscal year ends. by Sep 28, 2027

A deadline is the latest date the SEC's rules allow for its filer category. It is not a forecast of the day the company files. The proxy statement was last filed Sep 18, 2026.

Filings a yearinsider forms included
11243429476718
20092012202120222023202420252026

2026 counts to Nov 13, 2026.

Listing warning from its exchange (8-K item 3.01): 5 times in the last 36 months, the newest Dec 18, 2025.Officer or director change (8-K item 5.02): 2 times in the last 36 months, the newest Dec 23, 2024.SEC letters: 10 in the last 36 months, the newest Nov 12, 2025.A late-filing notice, Form NT 10-Q, filed May 15, 2025.
Insider forms 20

Insider forms (3, 4, 5 and 144) are counted each year but not listed here; the people and their trades are on the Ownership tab.

FiledFormWhat it is, in plain wordsPeriodAsk
Oct 23, 2026 8-K items 1.01, 3.03, 9.01 Major agreement signed; Change to shareholders' rights · Current report
Oct 5, 2026 SCHEDULE 13G Large holder notice
Sep 18, 2026 10-K Annual report Jun 30, 2026
Sep 18, 2026 DEFA14A Extra proxy material
Sep 18, 2026 DEFA14A Extra proxy material
Sep 18, 2026 DEF 14A Proxy statement Nov 2, 2026
Jul 28, 2026 SCHEDULE 13G/A Large holder update, amended
Jul 24, 2026 DEFA14A Extra proxy material
Jul 24, 2026 8-K items 1.01, 5.01, 7.01, 9.01 Major agreement signed; Change of control; Investor disclosure (Regulation FD) · Current report Jul 20, 2026
May 26, 2026 8-K item 8.01 Other event · Current report May 21, 2026
May 15, 2026 10-Q Quarterly report Mar 31, 2026
Feb 17, 2026 10-Q Quarterly report Dec 31, 2025
Feb 6, 2026 SCHEDULE 13G/A Large holder update, amended
Jan 8, 2026 8-K items 1.01, 1.02, 9.01 Major agreement signed; Major agreement ended · Current report Dec 31, 2025
Dec 29, 2025 SCHEDULE 13D/A Activist holder update, amended
Dec 18, 2025 8-K item 3.01 Listing warning from its exchange · Current report
Dec 17, 2025 8-K item 5.07 Shareholder vote · Current report Dec 12, 2025
Dec 8, 2025 DEFA14A Extra proxy material
Dec 8, 2025 DFAN14A Proxy material from an outside party
Dec 8, 2025 DFAN14A Proxy material from an outside party
Dec 4, 2025 DEFA14A Extra proxy material
Dec 3, 2025 DFAN14A Proxy material from an outside party
Dec 2, 2025 DFAN14A Proxy material from an outside party
Dec 2, 2025 SCHEDULE 13D/A Activist holder update, amended
Dec 1, 2025 DEFA14A Extra proxy material
Nov 28, 2025 SCHEDULE 13D/A Activist holder update, amended
Nov 26, 2025 DFAN14A Proxy material from an outside party
Nov 25, 2025 DEFA14A Extra proxy material
Nov 25, 2025 DFRN14A Form DFRN14A
Nov 24, 2025 DEFA14A Extra proxy material
Nov 24, 2025 DEFC14A Contested proxy statement
Nov 24, 2025 DEFC14A Contested proxy statement
Nov 18, 2025 SCHEDULE 13D/A Activist holder update, amended
Nov 14, 2025 424B5 Shelf offering
Nov 14, 2025 PREC14A Form PREC14A
Nov 14, 2025 10-Q Quarterly report Sep 30, 2025
Nov 12, 2025 DEFA14A Extra proxy material
Nov 12, 2025 CORRESP Reply to the SEC
Nov 12, 2025 PREC14A Form PREC14A
Nov 10, 2025 SCHEDULE 13D/A Activist holder update, amended
40 of 199 shown

Every row opens the filing on EDGAR. The plain words are the site's own for each form and each 8-K item; the complete history, insider forms included, is on EDGAR.

SI Assistanton NEUP · research, not advice